Linda Myers
About Linda Myers
Linda K. Myers, age 61, has served as an independent director of LCI Industries (LCII) since November 2022. She was a partner at Kirkland & Ellis LLP from 1996 through February 2022, serving on the Global Management Executive Committee and founding the firm’s Diversity Integration Task Force and Women’s Leadership Initiative. She brings strong financial and legal acumen and currently chairs LCII’s Corporate Governance, Nominating, and Sustainability Committee, with additional service on the Risk and Strategy, Acquisition, and Capital Deployment Committees .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Kirkland & Ellis LLP | Partner; Senior leadership | 1996–Feb 2022 | Global Management Executive Committee; Founded Diversity Integration Task Force; Founding member of Women’s Leadership Initiative |
External Roles
| Organization | Role | Start | Committees/Impact |
|---|---|---|---|
| Gibraltar Industries | Director | — | Chair, Nominating, Governance & Corporate Social Responsibility; Member, Capital Structure & Asset Management; Member, Compensation & Human Capital |
| Marex Group plc | Director | Jan 2024 | Chair, Remuneration Committee |
| Chelsea Lighting | Director | — | Director |
| Kinzie Capital Partners; National Philanthropic Trust; Chicago Shakespeare Theater; Lyric Opera of Chicago | Board leadership roles | — | Governance and civic leadership roles |
Board Governance
- Committee assignments: Chair, Corporate Governance, Nominating, and Sustainability (CGNS); Member, Risk; Member, Strategy, Acquisition, and Capital Deployment .
- Independence: Board determined in March 2025 that Myers has no material relationship with the Company; meets NYSE independence standards .
- Attendance: In 2024, Board held 7 meetings; all directors attended at least 75% of Board and committee meetings on which they served .
- Committee activity levels (FY 2024): Audit 7 meetings; Compensation & Human Capital 5; CGNS 3; Risk 4; Strategy, Acquisition & Capital Deployment 5 .
Fixed Compensation
| Component | Policy/Detail | FY 2024 Actual for Myers |
|---|---|---|
| Annual cash retainer | $100,000 (covers up to 20 Board/Committee meetings) | $115,000 (fees earned or paid in cash) |
| Chair fee | CGNS Chair: $15,000 | Included in cash total |
| Meeting fees | $1,500 per meeting beyond 20 | Not separately disclosed (cash total reflects policy) |
| Pay cadence | Paid quarterly | Paid quarterly |
| Consultant | Willis Towers Watson consulted for director comp mix/levels | — |
Performance Compensation
| Equity Award Type | Grant Detail | Vesting | FY 2024 Amount |
|---|---|---|---|
| RSUs (annual grant) | 1,354 RSUs granted in May 2024 at $110.83 per share (≈$150,000 value); grant-date fair value methodology | Vest in full on the earlier of first anniversary of grant or next annual shareholder meeting | Stock awards value: $150,064 |
| Options/other stock awards | Non-employee directors can receive options under plan; none granted in 2024 | — | None in 2024 |
| DSUs election (cash deferral option) | Directors may elect DSUs in lieu of cash (credited at 115% of deferred fee); some directors elected in 2024 (Gero, Reed, Mains) | Distributed as shares at end of deferral period; dividend equivalents accrue | Myers not listed among DSU electors |
Director equity grants are time-based RSUs; no performance metrics apply to director compensation . For context on LCII incentive metrics (executives, not directors): 2024 AIP used Adjusted EBIT (89.56% payout achieved) and a Cash Flow from Operations in Excess of Target metric (no payout); 2024 PSUs were tied to ROIC and Free Cash Flow as a percent of Operating Profit .
| LCII 2024 Incentive Metrics (NEOs, context) | Program | Outcome/Use |
|---|---|---|
| Adjusted EBIT | AIP | 89.56% payout achieved (executives) |
| Cash Flow from Operations in Excess of Target | AIP add-on | No payout (executives) |
| ROIC | PSUs | Performance measure (executives) |
| Free Cash Flow as % of Operating Profit | PSUs | Performance measure (executives) |
Other Directorships & Interlocks
- Current public boards: Gibraltar Industries; Marex Group plc .
- Additional roles: Chelsea Lighting; Kinzie Capital Partners; National Philanthropic Trust; Chicago Shakespeare Theater; Lyric Opera of Chicago .
- Interlocks/conflicts: No related-person transactions disclosed involving Myers; CGNS Committee (chaired by Myers) reviews and approves related person transactions and resolves director conflicts .
Expertise & Qualifications
- Financial/legal acumen; governance leadership; committee chair experience at public companies (Gibraltar, Marex) .
- Board effectiveness and succession oversight via CGNS Committee mandate, including executive succession planning and related-person transaction approvals .
Equity Ownership
| Holder | Beneficial Shares | Approx. % of Class | RSUs Held (12/31/2024) | Notes |
|---|---|---|---|---|
| Linda K. Myers | 2,093 | <1% (“*”) | 1,394 | RSUs vest May 15, 2025; RSUs counted separately from beneficial shares |
| Ownership guidelines (Directors) | Must hold 5x annual cash retainer (stock/RSUs/DSUs count; options do not) | Compliance | — | All non-employee directors satisfy guidelines or are within 5-year compliance window |
Governance Assessment
- Strengths: Independent director; chairs CGNS Committee overseeing board effectiveness, succession, and related-person transactions; robust director ownership guidelines (5x retainer) and time-based equity grants; all directors at least 75% attendance in 2024; active service on Risk and Strategy committees with defined oversight scopes .
- Compensation alignment: Director pay mix is simple and transparent—cash retainer plus annual RSUs (~$150k), with chair fees; no options granted to directors in 2024; DSU program encourages long-term ownership .
- Oversight quality: CGNS Committee chaired by Myers met 3 times in 2024; Compensation & Human Capital Committee met 5; Audit met 7; Risk met 4; Strategy met 5, indicating active committee oversight cadence .
- Red flags: No pledging/hedging disclosures for Myers identified; no Myers-related party transactions disclosed. The proxy includes a prohibition on hedging by directors section, and related-person transactions oversight is explicit under CGNS, which mitigates conflict risk .